文献速递外周动脉疾病

门诊与住院下肢动脉疾病腔内血运重建的成本效果分析:法国随机对照试验

Editor's Choice - A Cost Effectiveness Analysis of Outpatient versus Inpatient Hospitalisation for Lower Extremity Arterial Disease Endovascular Revascularisation in France: A Randomised Controlled Trial.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-01-05

AMBUVASC试验在法国9家公立和2家私立中心比较门诊与住院下肢动脉疾病腔内修复的成本效果。160例患者随机分组,改良意向治疗分析153例,门诊组围术期并发症20%、住院组18%(p=.81)。

要点

  • 门诊组与住院组围术期并发症率相似(20% vs 18%,p=.81)。
  • 门诊组因再入院更多导致总成本(差187.83欧元)和QALY(差0.00277)略高。

研究设计与样本

  • AMBUVASC为法国多中心前瞻性随机对照试验,在9家公立和2家私立中心开展。
  • 共随机160例患者(每组80例),改良意向治疗分析153例(门诊76例,住院77例)。
  • 主要终点为增量成本效果比(ICER),即每质量调整生命年(QALY)的成本,从社会视角分析,排除间接成本,时间跨度1个月。

主要发现

  • 门诊组和住院组围术期并发症率分别为20%(15起事件)和18%(14起事件),p=.81。
  • 门诊组总成本差异为187.83欧元(95%CI -275.68至651.34),QALY差异为0.00277(95%CI -0.00237至0.00791),均高于住院组,因再入院更多。

临床怎么用

  • 对于间歇性跛行患者的下肢动脉疾病腔内修复,选择门诊住院时需考虑再入院风险及成本效果。

局限性

  • 分析时间跨度仅1个月,可能未涵盖长期成本效果。
  • 分析排除了间接成本。
  • 缺失数据通过多重插补处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The AMBUVASC trial evaluated the cost effectiveness of outpatient vs. inpatient hospitalisation for endovascular repair of lower extremity arterial disease (LEAD). METHODS: AMBUVASC was a national multicentre, prospective, randomised controlled trial conducted in nine public and two private French centres. The primary endpoint was the incremental cost effectiveness ratio (ICER), defined by cost per quality adjusted life year (QALY). Analysis was conducted from a societal perspective, excluding indirect costs, and considering a one month time horizon. RESULTS: From 16 February 2016 to 29 May 2017, 160 patients were randomised (80 per group). A modified intention to treat analysis was performed with 153 patients (outpatient hospitalisation: n = 76; inpatient hospitalisation: n = 77). The patients mainly presented intermittent claudication (outpatient arm: 97%; inpatient arm: 92%). Rates of peri-operative complications were 20% (15 events) and 18% (14 events) for the outpatient and inpatient arms respectively (p = .81). Overall costs (difference: €187.83; 95% confidence interval [CI] -275.68-651.34) and QALYs (difference: 0.00277; 95% CI -0.00237 - 0.00791) were higher for outpatients due to more re-admissions than the inpatient arm. The mean ICER was €67 741 per QALY gained for the base case analysis with missing data imputed using multiple imputation by predictive mean matching. The outpatient procedure was not cost effective for a willingness to pay of €50 000 per QALY and the probability of being cost effective was only 59% for a €100 000/QALY threshold. CONCLUSION: Outpatient hospitalisation is not cost effective compared with inpatient hospitalisation for endovascular repair of patients with claudication at a €50 000/QALY threshold.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Gouëffic Y, Pin JL, Sabatier J, et al. Editor's Choice - A Cost Effectiveness Analysis of Outpatient versus Inpatient Hospitalisation for Lower Extremity Arterial Disease Endovascular Revascularisation in France: A Randomised Controlled Trial. Eur J Vasc Endovasc Surg. 2021. PMID: 33414066. doi:10.1016/j.ejvs.2020.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。